Because the children of today all deserve a tomorrow

Research Grant collaboration project with LoveOliver

Grace Kelly Childhood Cancer Trust announces £100,000 project collaborating with Scottish charity LoveOliver

The Grace Kelly Childhood Cancer Trust are proud to be able to announce that we have supported Scottish Charity LoveOliver to award £100,000 of funding to fund a vital research project into rhabdoid tumours and other rare types of childhood cancer.

The project that has received the award is entitled:

“Liquid biopsies and minimal residual disease measurements for the management of Malignant Rhabdoid Tumours and other SMARCB1 mutated tumours,” and is led by research scientist Dr Daniel Williamson at Newcastle University.

This project is primarily looking at the use of a certain type of liquid biopsy (blood samples) to measure their response to treatment protocols. This method could result in significant advances in how we treat these aggressive tumours.

The funding for this project has been provided by LoveOliver, and the research expertise has been provided by the Grace Kelly Childhood Cancer Trust Research Advisory Panel.

We are delighted to have been able to work in collaboration with this wonderful charity to help enable them to be sure that they are funding research of the highest possible quality.

It is a pleasure for two like-minded charities to come together to collaborate with the aim of helping to fund much needed research into rare childhood cancers, especially rhabdoid tumours.

We are proud to have been able to support LoveOliver to fund this promising project. Not all charities have their own research advisory board that enables them to be certain they are funding the best possible projects, so the team at the Grace Kelly Trust are proud to have been able to offer our expertise to LoveOliver and to collaborate on this project. Rhabdoid tumours and other rare sarcomas have very poor survival rates in children, and by charities working together, we hope that it will lead to more significant advances. It is a pleasure to work with LoveOliver and I hope that it will be the first of a number of ways that our charities can continue to collaborate going forwards.

Dr Jen Kelly - CEO

Jennifer Gill, CEO said:

“We are proud to be funding this project in partnership with GKCCT, in memory of Oliver and Grace, who were born just one day apart in 2010, and who both lost their lives to rhabdoid tumours. We hope it will help to make a real difference to the treatment and prognosis of all those children who will sadly have to face a rhabdoid diagnosis in the future.“

The Grace Kelly Childhood Cancer Trust are accredited members of the AMRC (Association of Medical Research Charities) after having been on the way that it funds its research. AMRC membership shows that we fund our research using the research gold standard processes of open project funding rounds, external written scientific reviews by scientists who are experts in their field and then scored and ranked by our expert led Research Advisory Panel.

This means that we can be sure that the funds we award make the biggest possible difference to children with cancer diagnosed now and in the future.

To find out more about how we award research funding, and our membership as an accredited member of the AMRC, please see how we fund research.

Search